--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------
01.10.2011
MORRISVILLE, NC, September 30, 2011— Oxygen Biotherapeutics, Inc. (NASDAQ & SIX
Swiss Exchange: OXBT) today announced that Ronald R. Blanck, DO, was appointed
Chairman of the Board of Directors of the company.
The company also reported that in light of the shareholder vote received today
at the General Annual Meeting of Shareholders Rene A. Eckert and J. Melville
Engle resigned as directors of the company. Neither of the resignations was the
result of any disagreement with the company or the Oxygen Board of Directors.
In a letter to the board, Mr. Engle said, "I respect the vote as an indicator of
desired change and am abiding thereto. I believe in the company and I wish the
best for our shareholders in the future."
In a separate letter to the board, Mr. Eckert said, "I wish to make clear that
my resignation is not due to any disagreement with the company, its Board of
Directors or its management, and each continues to have my full support."
This board change brings the Oxygen Board of Directors to three members. At
this time, the company will evaluate the existing board structure and future
needs.
In an unrelated matter, the company also announced that Chief Medical Officer
Dr. Gerald Klein notified the company of his intent to resign in October because
he accepted a position with another company.
"We are sorry to see Dr. Klein, Mr. Eckert and Mr. Engle leave but we understand
and respect their decisions. We wish to thank them for their service to our
company. We highly value the insight they have provided and appreciate their
contributions," said Chief Financial Officer and Interim Chief Executive Officer
Michael Jebsen.
"We are pleased that Dr. Blanck has agreed to accept the chairmanship of our
board. His medical expertise and leadership abilities will be invaluable to us
as we navigate the clinical development of medical products," Mr. Jebsen added.
end of ad-hoc-announcement
================================================================================
About Ronald R. Blanck, DO
Dr. Blanck is chairman of Martin, Blanck & Associates, a federal health services
consulting firm. He completed a 32-year military career as Lieutenant General
and Surgeon General of the U.S. Army, and commander of the U.S. Army Military
Command. He also served as commander of Walter Reed Medical Center and the
North Atlantic Region Medical Command. His background also includes serving as
president of the University of North Texas Health Science Center at Fort Worth.
About Oxygen Biotherapeutics, Inc.
Headquartered in Morrisville, NC, Oxygen Biotherapeutics, Inc. is developing
medical and cosmetic products that efficiently deliver oxygen to tissues in the
body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic
oxygen carrier product called Oxycyte® that is being formulated for both
intravenous and topical delivery. The company has commercialized its DERMACYTE®
line of oxygen-rich skin care products. In addition, the company is focused on
PFC-based oxygen carriers for use in traumatic brain injury, decompression
sickness, and topical wound healing. See www.oxybiomed.com
[1], or
www.DermacyteUS.com for more information.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company’s judgment as of
the date of this release. These statements include the management transition,
and expansion of research and development of the Oxycyte product line, including
the timing of the introduction of these new products. The forward-looking
statements are subject to a number of risks and uncertainties including matters
beyond the company’s control that could lead to delays in new product
introductions and customer acceptance of these new products, and other risks and
uncertainties as described in our filings with the Securities and Exchange
Commission, including in the current annual report on Form 10-K filed on July
15, 2011. The company disclaims any intent or obligation to update these
forward-looking statements beyond the date of this release. This caution is made
under the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Further inquiry note:
Ellen Corliss
Vice President, Corporate Communications
& Investor Relations
Oxygen Biotherapeutics, Inc
One Copley Pkwy, Suite 490
Morrisville, NC 27560
Direct Telephone: +1 919 855 2112
Direct Fax: +1 919 806 4417
Email:
Diese E-Mail-Adresse ist gegen Spambots geschützt! JavaScript muss aktiviert werden, damit sie angezeigt werden kann.
end of announcement euro adhoc
--------------------------------------------------------------------------------
issuer: Oxygen Biotherapeutics Inc.
One Copley Parkway, Suite 490
US-27560 Morrisville, NC
phone: +1 (919) 855 21 12
FAX: +1 (919) 806 44 17
mail:
Diese E-Mail-Adresse ist gegen Spambots geschützt! JavaScript muss aktiviert werden, damit sie angezeigt werden kann.
WWW:
www.oxybiomed.com
sector: Biotechnology
ISIN: US69207P2092
indexes: SSIRT
stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange
language: English
